






PHARMACEUTICAL 2017

Northwest Biotherapeutics INC Rank 274 of 308

The relative strengths and weaknesses of Northwest Biotherapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Northwest Biotherapeutics INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Northwest Biotherapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 145% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	7,884
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	76,405
Liabilities, Non-Current	3,000
Other Assets	44,707
Other Compr. Net Income	1,971
Other Expenses	14,216
Other Liabilities	0
Other Net Income	4,327
Other Revenues	623
Property and Equipment	315
Research and Development	60,081
Selling, General and Administrative Expense	10,867

Output Variable	Value in 1000 USD
Assets	52,906
Liabilities	79,405
Expenses	85,164
Revenues	623
Stockholders Equity	-26,499
Net Income	-80,214
Comprehensive Net Income	-79,228
BaseVar	112,198
ECR before LimitedLiability	-207%
Economic Capital Ratio	100%